Compare BLND & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | FULC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.8M | 285.4M |
| IPO Year | 2021 | 2019 |
| Metric | BLND | FULC |
|---|---|---|
| Price | $0.99 | $3.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $2.96 | ★ $3.67 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $3.71 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $2.83 |
| 52 Week High | $3.62 | $15.74 |
| Indicator | BLND | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 29.15 | 51.35 |
| Support Level | N/A | $3.75 |
| Resistance Level | $1.60 | $3.91 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.94 | 52.50 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.